Treatment of Rapidly Progressive Glomerulonephritis (RPGN)

Immediate Diagnostic and Treatment Approach

• The American Journal of Kidney Diseases and Kidney International recommend initiating aggressive immunosuppression immediately with high-dose corticosteroids combined with either cyclophosphamide or rituximab for patients with RPGN, without waiting for biopsy confirmation if clinical suspicion is high 1, 2, 3, 4, 5
• Start immunosuppression before biopsy results if clinical presentation is compatible with RPGN and serologies are positive or pending, according to Kidney International 4, 5
• The only absolute requirement before starting treatment is excluding infection with as much certainty as possible, as stated by Kidney International 4, 5
• Obtain kidney biopsy when feasible for diagnosis confirmation and prognosis, but do not delay treatment waiting for it, as recommended by Kidney International 4, 5

Treatment Regimens by Etiology

• For ANCA-associated vasculitis, induction therapy consists of either cyclophosphamide or rituximab plus high-dose corticosteroids, according to the American Journal of Kidney Diseases and Kidney International 1, 2, 3, 4, 5
• The American Journal of Kidney Diseases recommends pulse IV methylprednisolone 500-1000 mg daily for 3 consecutive days, followed by oral prednisone starting at 1 mg/kg/day with gradual taper over at least 6 months 1, 2, 3, 6, 7, 8
• Cyclophosphamide is preferred when severe kidney dysfunction is present, according to Kidney International 4, 5
• Rituximab is preferred when less severe kidney dysfunction is present or when there are concerns about cyclophosphamide toxicity, as stated by Kidney International and the American Journal of Kidney Diseases 4, 5, 8

Critical Caveats and Contraindications

• Withhold immunosuppression in patients with eGFR <30 mL/min/1.73 m² and chronic changes on biopsy, unless there is active necrotizing or crescentic GN, according to the American Journal of Kidney Diseases 1, 2, 3
• Treat patients with preserved renal parenchyma and acute tubular necrosis, as recommended by the American Journal of Kidney Diseases 1, 2, 3

Plasma Exchange Controversy

• Plasma exchange is not routinely recommended for ANCA vasculitis based on the PEXIVAS trial, according to Kidney International 4, 5
• Plasma exchange is recommended for anti-GBM disease and ANCA vasculitis that overlaps with anti-GBM disease, as stated by the American Journal of Kidney Diseases and Kidney International 4, 5, 6, 7, 8

Management of Rapidly Progressive Glomerulonephritis (RPGN)

Initial Treatment Approach

• The American Journal of Kidney Diseases recommends initiating treatment based on positive MPO or PR3 ANCA serology combined with compatible clinical presentation, even before biopsy confirmation, using cyclophosphamide or rituximab plus high-dose corticosteroids 9

Disease-Specific Considerations

• For anti-GBM antibody disease, the American Journal of Kidney Diseases suggests adding plasmapheresis to cyclophosphamide and glucocorticoids for all patients except those with 100% crescents, >50% global glomerulosclerosis, dialysis-dependent without pulmonary hemorrhage 10
• The American Journal of Kidney Diseases recommends treating aggressively even without alveolar hemorrhage if there is potential renal viability in anti-GBM antibody disease 10
• Patients presenting on dialysis have >90% chance of remaining dialysis-dependent, so treatment should be reserved for those with pulmonary hemorrhage or recent dialysis initiation in anti-GBM antibody disease 10

Immune Complex-Mediated RPGN

• The American Journal of Kidney Diseases recommends treating with high-dose glucocorticoids and cyclophosphamide, similar to ANCA-associated vasculitis regimen, for crescentic presentation with rapidly progressive disease 11
• Consider rituximab as alternative to cyclophosphamide in immune complex-mediated RPGN 11

Critical Contraindications to Immunosuppression

• Withhold immunosuppression in patients with eGFR <30 mL/min/1.73 m² ONLY if kidney biopsy shows high degree of interstitial fibrosis and tubular atrophy, extensive glomerulosclerosis, or absence of active necrotizing or crescentic lesions 11
• The decision should be based on overall renal viability assessed by biopsy findings, not eGFR alone 11

Common Pitfalls to Avoid

• Delaying treatment while waiting for biopsy results—the combination of compatible clinical presentation and positive serology is sufficient to begin therapy 9
• Treating patients with advanced chronic kidney disease and extensive fibrosis on biopsy—these patients will not benefit and face only toxicity risk 11
• Using calcineurin inhibitors (tacrolimus, cyclosporine) for immune complex RPGN—these cause immune complex-negative angiopathy and thrombotic microangiopathy 11
• Assuming all patients with low eGFR should not be treated—active crescentic disease warrants treatment regardless of eGFR 11

Management Recommendations for Immune Complex‑Mediated Rapidly Progressive Glomerulonephritis

Pre‑treatment Evaluation

• Prior to initiating immunosuppression, clinicians must exclude active infection with the highest possible certainty to avoid worsening infectious complications. This prerequisite is emphasized in the 2021 Kidney International review. 12

Role of Plasma Exchange

• Routine plasma exchange is not recommended for immune‑complex mediated RPGN because current evidence does not demonstrate a clear benefit; it should be reserved for exceptional situations (e.g., severe pulmonary hemorrhage or overlap with anti‑GBM disease). 12

Guideline‑Based Therapeutic Approach

• The 2021 KDIGO guideline advises a tailored, nuanced treatment strategy for idiopathic immune‑complex GN, matching therapy intensity to disease severity and histologic activity while avoiding unnecessary aggressive immunosuppression in low‑risk cases. 12

Immediate Initiation of Immunosuppression in Crescentic IgA Nephropathy

Clinical Decision‑Making

• Initiate high‑dose corticosteroids and cyclophosphamide promptly when the clinical picture (rapid rise in serum creatinine, active urinary sediment with glomerular hematuria and proteinuria) strongly suggests rapidly progressive glomerulonephritis, without waiting for biopsy confirmation. 13
• The only absolute contraindication to immediate immunosuppression is the presence of an active infection; infection must be excluded with the highest possible certainty before therapy begins. 13

Choice of Induction Agent

• Rituximab may be used as an alternative to cyclophosphamide in patients in whom cyclophosphamide toxicity is a concern, but cyclophosphamide remains the preferred agent for those with severe renal dysfunction (e.g., serum creatinine > 4 mg/dL). 13

Common Pitfalls to Avoid

• Do not postpone therapy while awaiting biopsy results if the clinical syndrome is compatible with RPGN; treatment should start based on clinical criteria alone. 13
• Do not commence immunosuppression without first ruling out active infection, as infection is the sole absolute contraindication to immediate therapy. 13

Corticosteroid Tapering Strategy

• After the initial high‑dose phase, oral prednisolone should be tapered gradually over a minimum of six months to reduce the risk of relapse and steroid‑related adverse effects. 14

Immediate Initiation and Management of Type 3 RPGN (Pauci‑Immune ANCA‑Associated Vasculitis)

Immediate Treatment Initiation

• Initiate immunosuppression (rituximab or cyclophosphamide plus glucocorticoids) as soon as the clinical picture suggests ANCA‑associated vasculitis and MPO‑ or PR3‑ANCA is positive, without awaiting kidney‑biopsy confirmation. Evidence: prospective cohort data (high‑quality) [15][16]
• Do not postpone therapy while waiting for biopsy results when small‑vessel vasculitis is clinically likely and ANCA serology is positive or pending. Evidence: retrospective multicenter series (moderate) [17][18]19
• The only absolute prerequisite before starting immunosuppression is the exclusion of active infection to the greatest possible certainty. Evidence: expert consensus (moderate) [17][18]
• Obtain a kidney biopsy when feasible to confirm diagnosis and inform prognosis, but prioritize treatment initiation. Evidence: expert consensus (moderate) [17][18]

Induction Therapy – Choice of Immunosuppressive Agent

• Rituximab is preferred for PR3‑ANCA‑positive patients, delivering superior remission (odds ratio ≈ 2.1 at 6 months; OR ≈ 3.6–4.3 in relapsing disease). Evidence: randomized controlled trials (high) [15][16]20
• Rituximab is also favored in relapsing disease regardless of ANCA subtype. Evidence: RCTs (high) [15][16]
• Cyclophosphamide is preferred when severe renal dysfunction is present (serum creatinine > 4 mg/dL) because data for rituximab are limited in this setting. Evidence: observational data (moderate) [17][15][16][19]
• In very severe glomerulonephritis, a regimen combining two intravenous cyclophosphamide pulses with rituximab may be considered. Evidence: expert opinion (low) 17
• For MPO‑ANCA patients, no clear superiority of rituximab over cyclophosphamide has been demonstrated. Evidence: head‑to‑head RCTs (moderate) [15][16]20

Induction Therapy – Glucocorticoid Dosing

• Standard approach: Intravenous methylprednisolone 1–3 g for severe presentations (widely used, not RCT‑tested) followed by oral prednisone/prednisolone 1 mg/kg/day (traditional dose in most RCTs). Evidence: clinical practice guidelines (low‑moderate) [15][16]
• A rapid taper (as in the PEXIVAS trial) is as effective as a standard taper but yields fewer adverse events in patients with GFR < 50 mL/min/1.73 m². Evidence: large RCT (high) [15][16]
• Reduced‑dose regimen (prednisolone 0.5 mg/kg/day) combined with rituximab was non‑inferior to the standard dose and resulted in fewer severe infections (LoVAS trial). Evidence: RCT (high) [15][16]20
• Caveat: LoVAS excluded patients with eGFR < 15 mL/min/1.73 m², severe alveolar hemorrhage, and was conducted in a Japanese cohort predominately with MPO‑ANCA disease. Evidence: trial design (moderate) [15][16]20

Glucocorticoid‑Sparing Agent

• Avacopan (30 mg twice daily) was non‑inferior to standard glucocorticoid regimens for achieving remission at week 26 (72.3 % vs 70.1 %). Evidence: ADVOCATE RCT (high) 20
• Avacopan accelerated reduction of albuminuria and improved renal function, especially in patients with eGFR < 20 mL/min/1.73 m². Evidence: ADVOCATE subgroup analysis (moderate) 20
• Caveat: ADVOCATE excluded patients with eGFR < 15 mL/min/1.73 m² and those with severe alveolar hemorrhage requiring mechanical ventilation. Evidence: trial eligibility criteria (moderate) 20

Plasma Exchange

• Routine plasma exchange is not recommended for ANCA‑associated vasculitis based on the PEXIVAS trial. Evidence: large RCT (high) 17
• Plasma exchange should be employed when ANCA‑associated vasculitis co‑exists with anti‑GBM antibody disease. Evidence: expert consensus (moderate) 17

Maintenance Therapy

• Rituximab is preferred over azathioprine for long‑term maintenance. Evidence: RCT (high) 17
• A minimum of 18 months of maintenance immunosuppression is advised; up to 4 years of azathioprine has been used in practice. Evidence: cohort studies (moderate) 17
• Discontinuation of maintenance therapy can be considered after individualized assessment of relapse risk. Evidence: expert consensus (moderate) 17

Relapse Risk Factors

• Higher relapse risk is associated with:
  Evidence: multivariate analyses from prospective registries (moderate) 17

Infection Considerations

• Infection remains the leading cause of death in RPGN patients; therefore, rigorous exclusion of infection before initiating immunosuppression is essential. Evidence: observational data (moderate) [17][18]

Rapidly Progressive Glomerulonephritis (RPGN): Evidence‑Based Diagnostic and Therapeutic Recommendations

Diagnostic Work‑Up

• Immediate autoimmune serology panel – Order ANCA (MPO and PR3), anti‑GBM antibodies, ANA, and complement C3/C4 as soon as RPGN is suspected to guide etiology and early treatment decisions. 21
• Kidney biopsy when feasible – Perform a renal biopsy to confirm the underlying pathology and to differentiate active necrotizing lesions from chronic scarring; however, do not postpone immunosuppressive therapy while awaiting biopsy results if the clinical picture and serologies are compatible with RPGN. 21
• Potential false‑negative anti‑GBM testing – Anti‑GBM antibodies may be undetectable in approximately 10 % of true anti‑GBM disease cases, underscoring the importance of obtaining tissue diagnosis whenever it can be safely performed. 21

Anti‑GBM Antibody Disease Management

• Standard induction regimen – Initiate combination therapy with cyclophosphamide, high‑dose glucocorticoids, and therapeutic plasma exchange for all patients with confirmed anti‑GBM disease, except those who present already on dialysis and have biopsy findings of 100 % crescents or > 50 % global glomerulosclerosis without pulmonary hemorrhage. 21
• Aggressive treatment despite absent alveolar hemorrhage – Even in the absence of lung involvement, pursue the full induction protocol when clinical and histologic features suggest that renal parenchyma remains potentially salvageable. 21

Plasma‑Exchange Indications

• Recommended for anti‑GBM disease – Therapeutic plasma exchange is a core component of induction therapy for anti‑GBM antibody–mediated RPGN, aiming to remove circulating pathogenic antibodies. 21
• Indicated in overlapping anti‑GBM/ANCA vasculitis – When anti‑GBM disease co‑exists with ANCA‑associated vasculitis, plasma exchange should also be employed as part of the induction strategy. 21

Pulse Corticosteroid Therapy in Hepatitis B‑Associated Rapidly Progressive Glomerulonephritis

Indications for Short‑Course Steroids

• In patients with severe vasculitis or rapidly progressive glomerulonephritis (RPGN) linked to chronic hepatitis B, a brief course of high‑dose corticosteroids may be considered, but only when combined with antiviral therapy (moderate‑quality expert consensus)【22】【23】【24】【25】.

Immediate Antiviral Management

• Antiviral treatment should be started immediately on diagnosis of HBV‑related RPGN, using nucleos(t)ide analogues such as entecavir or tenofovir (the latter avoided when possible because of added nephrotoxicity) in accordance with standard HBV treatment guidelines (moderate‑quality evidence)【22】【23】【24】【25】.
• Dose adjustments of all FDA‑approved nucleos(t)ide analogues are required for reduced glomerular filtration rate (moderate‑quality evidence)【22】【23】.

Pulse Methylprednisolone Regimen

• For severe/rapidly progressive disease, administer pulse intravenous methylprednisolone 500–1000 mg daily for 3 consecutive days, followed by oral prednisone 0.5–1 mg/kg/day with a gradual taper over ≥6 months (moderate‑quality evidence)【26】.

Additional Immunosuppressive Options (Crescentic Disease)

• In necrotizing or crescentic GN, cyclophosphamide (0.5–1 g IV every 2–4 weeks) or rituximab may be added only if antiviral coverage is maintained (moderate‑quality evidence)【22】【23】【25】.

Contraindications & Safety Caveats

• Routine immunosuppression for HBV‑related GN is not supported because of the risk of viral replication, worsening renal function, and hepatitis flare when immunosuppression is withdrawn (low‑quality evidence)【22】【23】【24】【25】.
• The exception is RPGN or vasculitis, where short‑course steroids are justified (moderate‑quality evidence)【22】【23】【24】【25】.
• Prior to rituximab, HBV screening (HBsAg, anti‑HBc, anti‑Hs) is mandatory; failure to screen has led to fatal hepatitis due to viral reactivation (moderate‑quality evidence)【22】【23】【25】.
• Hepatology consultation is required for prophylactic antiviral planning before rituximab use (moderate‑quality evidence)【22】【23】【25】.
• Tenofovir and adefovir should be avoided when feasible because of their known nephrotoxic potential (moderate‑quality evidence)【22】【23】.

Evidence Quality Overview

Monitoring & Follow‑Up

• After initiating therapy, monitor HBV DNA levels and liver enzymes weekly during the first month to detect reactivation early (moderate‑quality evidence)【27】.

All bullet points are derived from cited references and reflect the current guideline‑based recommendations for managing hepatitis B‑associated rapidly progressive glomerulonephritis.